Sanofi (NASDAQ:SNY) Reaches New 1-Year Low – What’s Next?

Sanofi (NASDAQ:SNY)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $43.32 and last traded at $43.61, with a volume of 319484 shares changing hands. The stock had previously closed at $44.06.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Price Performance

The firm has a 50-day simple moving average of $46.55 and a 200-day simple moving average of $48.08. The firm has a market capitalization of $110.58 billion, a PE ratio of 12.59, a PEG ratio of 1.13 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. raised its holdings in Sanofi by 31.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 523,168 shares of the company’s stock worth $25,353,000 after purchasing an additional 126,381 shares during the period. World Investment Advisors grew its holdings in Sanofi by 8.1% during the fourth quarter. World Investment Advisors now owns 73,792 shares of the company’s stock valued at $3,576,000 after purchasing an additional 5,553 shares during the period. Advisortrust Partners LLC purchased a new stake in Sanofi in the fourth quarter worth about $437,000. Hsbc Holdings PLC increased its position in Sanofi by 3,426.0% in the fourth quarter. Hsbc Holdings PLC now owns 205,917 shares of the company’s stock worth $9,987,000 after buying an additional 200,077 shares in the last quarter. Finally, Bayban bought a new position in shares of Sanofi in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.